Phospholipid liposomes and prolactin secretion: effects on spontaneous and drug-induced hyperprolactinaemia.
Bovine brain phospholipid liposomes (BC-PL) reduce plasma prolactin (PRL) levels in humans after acute administration and counteract the metoclopramide- and sulpiride-induced hyperprolactinaemia. However, BC-PL, like nomifensine, a dopamine (DA) reuptake inhibitor and therefore an indirect dopaminergic compound, does not influence TRH-induced hyperprolactinaemia. Moreover, BC-PL and nomifensine reduce plasma PRL levels in hyperprolactinaemic PCO syndromes but not in PRL secreting pituitary adenomas. The results obtained indicate that BC-PL antagonizes the DA blockade-induced hyperprolactinaemia and that the main site of action of BC-PL seems to be at the hypothalamic level; however a concomitant pituitary effect cannot be ruled out.
D000328:Adult; D000818:Animals; D002417:Cattle; D005260:Female; D006801:Humans; D008081:Liposomes / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood*; D011954:Receptors, Dopamine / Q000187:drug effects
D008081:Liposomes; D010743:Phospholipids; D011954:Receptors, Dopamine; D011388:Prolactin